Current Report Filing (8-k)
January 18 2017 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 18, 2017 (January 18, 2017)
ARCA biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
000-22873
|
36-3855489
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
11080 CirclePoint Road, Suite 140, Westminster, CO 80020
(Address of Principal Executive Offices) (Zip Code)
(720) 940-2200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.4
25)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section
8
—
Other Events
On January 18, 2017, ARCA biopharma, Inc. announced that the 150
th
patient has been randomized into GENETIC-AF, a seamless design Phase 2B/3 clinical trial evaluating Gencaro
TM
(bucindolol hydrochloride) as a potential treatment for atrial fibrillation. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press Release titled “ARCA biopharma Announces 150
th
Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial” dated January 18, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
Dated: January 18, 2017
|
|
|
|
|
ARCA biopharma, Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Brian L. Selby
|
|
|
Name:
|
Brian L. Selby
|
|
|
Title:
|
Vice President, Finance and Chief Accounting Officer
|
INDEX TO EXHIBITS
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press Release titled “ARCA biopharma Announces 150
th
Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial” dated January 18, 2017.
|
|
|
|
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Sep 2023 to Sep 2024